The following adverse events can be observed (based on the post-marketing data source):
Psychiatric disorders: Confusional state, aggression, insomnia.
Gastrointestinal disorders: Nausea, abdominal pain, diarrhoea, vomiting, gastrointestinal disorder, dyspepsia.
Nervous system disorders: Dizziness, flushing.
Metabolism and nutrition disorders: Hypercalcaemia, hypercalciuria, decreased appetite, tetany.
Skin and subcutaneous tissue disorders: Pruritus, urticaria, rash, hyperhidrosis.
The side effects are the result of overdose.
Depending on the dose and duration of treatment, severe and prolonged hypercalcaemia with its acute (cardiac arrhythmias, nausea, vomiting, psychic symptoms, disturbances of consciousness) and chronic (increased urgency to urinate, increased thirst, loss of appetite, weight loss, kidney stones, kidney calcification, calcification in tissues outside the skeleton) consequences can occur. A fatal outcome has been reported in very rare cases. (See Precautions as well as Interactions. Furthermore, refer also to Overdosage).
Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
View ADR Monitoring Form